- Source : Globenewswire
- Date : 2021-07-29
- Event type : Pre Clinical
- Companies : Catalent, Inc., TFF Pharmaceuticals, Inc.
Catalent Biologics Has Been Selected to Conduct Cell Line Development
TFF Pharmaceuticals and Augmenta also announced that Catalent Biologics has been selected to conduct cell line development utilizing their proprietary GPEx® platform and to lead drug substance manufacturing and scale-up efforts for AUG-3387 as the program advances through clinical development. Commenting on the agreement, Dr. Emig continued, “With AUG-3387 quickly emerging as a promising treatment against COVID-19, including for currently dominant variants, the selection of the CDMO is a critical decision along our development pathway. As one of the leading global providers of advanced biologics, Catalent brings exceptionally strong expertise in manufacturing of monoclonal antibodies. Augmenta and TFF look forward to working with them as the AUG-3387 program continues to advance.”
Reference News > https://www.pharmacircle.com/one_news.php?id=610950